Of note, the authors treated T cell-depleted LMP1+ mice with low doses of recombinant NKG2D-Fc, which can trigger complement- and cell-dependent cytotoxicity, significantly reducing tumor growth and prolonging survival; therefore, they suggested that optimized doses of NKG2D-Fc have great potential in the treatment of EBV-driven pathologies, such as EBV+ PTLD, which displayed high (unspecified) ligand expression when stained with NKG2D-Fc [100]. This evidence concerns the gene KLRK1 and post-transplant lymphoproliferative disease.